Department of Gastroenterology, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, 710004, China.
Pulmonary and Critical Care Medicine, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, 710004, China.
Dig Dis Sci. 2022 Dec;67(12):5580-5592. doi: 10.1007/s10620-022-07588-4. Epub 2022 Jul 25.
Recent studies have shown that changes in the intestinal microbiota contribute to the pathogenesis of irritable bowel syndrome (IBS). This study aimed to investigate the characteristics of the fecal and intestinal mucosal microbiota in IBS patients, and the correlation between microbiota and clinical manifestations.
Fecal and intestinal mucosal samples were collected from 14 constipation-predominant IBS (IBS-C) patients, 20 diarrhea-predominant IBS (IBS-D) patients, and 20 healthy controls (HCs). 16S rRNA gene sequencing and fluorescence in situ hybridization were used for the analysis of samples.
Community richness and diversity of the fecal microbiota in IBS patients were significantly reduced compared with the HCs. The mucosal samples in IBS patients showed decreased Bifidobacterium and increased Bacteroides caccae compared with HCs; Eubacterium and Roseburia were decreased in IBS-C patients and increased in IBS-D patients. A comparison of the fecal and mucosal microbiota in IBS patients showed significantly increased Bifidobacterium in fecal samples and a decrease in mucosal samples in IBS-C patients; Bacteroides caccae and Roseburia were significantly reduced in fecal samples and increased in mucosal samples of IBS patients. A correlation between microbiota and clinical manifestations in IBS patients showed that Bacteroides caccae and Roseburia in fecal samples and Bifidobacterium and Eubacterium in mucosal samples were associated with abdominal pain and distention.
Distinct differences exist between the fecal and intestinal mucosal microbiota in IBS patients, with the changes in the latter appearing more consistent with the pathophysiology of IBS. Changes in intestinal microbiota were associated with the clinical manifestations in IBS.
最近的研究表明，肠道微生物群的变化有助于肠易激综合征（IBS）的发病机制。本研究旨在探讨 IBS 患者粪便和肠黏膜微生物群的特征，以及微生物群与临床表现之间的相关性。
收集了 14 例便秘型 IBS（IBS-C）患者、20 例腹泻型 IBS（IBS-D）患者和 20 例健康对照（HCs）的粪便和肠黏膜样本。采用 16S rRNA 基因测序和荧光原位杂交技术对样本进行分析。
与 HCs 相比，IBS 患者的粪便微生物群丰富度和多样性明显降低。IBS 患者的黏膜样本中双歧杆菌减少，而艰难梭菌增加；与 HCs 相比，IBS-C 患者的真杆菌和罗氏菌减少，而 IBS-D 患者的增加。IBS 患者粪便和黏膜微生物群的比较显示，IBS-C 患者粪便中双歧杆菌显著增加，而黏膜样本中减少；艰难梭菌和罗氏菌在粪便样本中显著减少，而在黏膜样本中增加。IBS 患者的微生物群与临床表现之间的相关性研究表明，粪便中的艰难梭菌和罗氏菌以及黏膜中的双歧杆菌和真杆菌与腹痛和腹胀有关。
IBS 患者的粪便和肠黏膜微生物群存在明显差异，后者的变化更符合 IBS 的病理生理学。肠道微生物群的变化与 IBS 的临床表现有关。
